Synlogic

Synlogic (NASDAQ: SYBX) is working at the cross section of biology and engineering, advancing a new class of medicines for patients. Synthetic Biotic medicines are living biotherapeutics, specifically designed to address the underlying drivers of disease.

Headquarters Cambridge, MA
Website www.synlogictx.com
Twitter @synlogic_tx​
Pipeline Phase 2 clinical trials
Partners AbbVie